NCT04406064

Viral Specific T-cells for Treatment of COVID-19

Viral Specific T-cells (VSTs) for Treatment of SARS-CoV-2/COVID-19

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Children's Hospital Medical Center, Cincinnati · Academic / Other
• Sex: All
• Age: 1 Day
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) when given in the presence of COVID-19 signs and symptoms, caused by the virus SARS-CoV-2. VSTs are cells specially designed to fight viral infections. These cells are created from a blood sample collected from a donor who has recovered from COVID-19 infection. VSTs are investigational meaning that they are not approved by the Food and Drug Administration (FDA). COVID-19 is a new virus and treatment options are evolving rapidly. VSTs have been successfully used to treat many different viral infections and may be beneficial in treating COVID-19 in the absence of other treatments.

Conditions

• Viral Infection

Interventions

Type	Name	Description
BIOLOGICAL	Viral Specific T-cells (VSTs)	VSTs will be infused into study participants who have evidence of SARS-CoV-2 infection.

Timeline

• Start date: 2021-01-01
• Primary completion: 2024-06-01
• Completion: 2025-06-01
• First posted: 2020-05-28
• Last updated: 2021-01-19

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study